Bionano Genomics, Inc. (BNGO) announced that three independently authored, peer-reviewed studies have demonstrated that optical genome mapping can uncover clinically significant structural genomic alterations across MDS, AML, and therapy-related myeloid neoplasms.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.